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ABSTRACT
Background    For patients with reactivation of human 
cytomegalovirus (CMV), a highly sensitive and accurate 
CMV quantification system is essential to monitor viral 
load. 
Methods    We constructed a real-time detection PCR 
(RTD-PCR) system for CMV DNA and evaluated its 
linearity, lower detection limit, dynamic range and ac-
curacy using two CMV standards. We used 219 clinical 
samples derived from 101 patients to compare the sys-
tem with the pp65 antigen test.
Results    The 95% detection limit was determined to be 
556 IU/mL (95% CI, 440–797 IU/mL), and the quantifi-
cation range was between 102 and 106 copies or IU/mL 
(r = 0.996, 0.999, respectively). The coefficients of varia-
tion of inter-assay reproducibility assessed in each three 
different runs were 2.5% at 1,000 IU/mL and 1.6% at 
10,000 IU/mL. The coefficients of variation of intra-as-
say variability by testing the same samples three times 
in a single run were 1.8–3.6% and 0.4–1.9%, respective-
ly. The concordance between antigenemia and plasma 
or serum CMV DNA levels was a good correlation (r = 
0.695, P < 0.01). 
Conclusion    We constructed the RTD-PCR system 
which enables accurate evaluation of CMV reactivation 
by monitoring of viral load in immunosuppressed or im-
munocompromised patients. 
Key words    CMV antigenemia, cytomegalovirus, 
quantification,  RTD-PCR
Cytomegalovirus (CMV) is a DNA virus that belongs to 
the herpes virus family, and often causes severe disease 
in immunosuppressed or immunocompromised patients. 
It is one of the most frequently occurring complications 
after hematopoietic stem cell transplantation and solid 
organ transplantation.1, 2
 CMV establishes latency in cells of the myeloid 
lineage following primary infection. The CMV antigen-
emia test is the most widely used quantitative assay for 
the diagnosis and follow-up of CMV infection, which 
becomes positive prior to the onset of CMV disease.3–5
 The CMV antigenemia test made it possible to start 
the administration of antiviral agents as the preemptive 
therapy when CMV antigen-positive cells were detected 
in a certain amount. However, the CMV antigenemia 
test has disadvantages such as long inspection time and 
complicated procedures. Various reports have been 
made about the usefulness of real-time PCR to quantify 
CMV DNA in recent years. One study comparing the 
usefulness of quantitative PCR system and CMV anti-
genemia tests for monitoring CMV reactivation showed 
that quantitative PCR have sensitivity equal to or more 
than that of CMV antigenemia.6–9 A quantitative PCR 
system for CMV DNA is commercially available and so 
expensive that it is not covered by health insurance in 
Japan. The aim of this study is to construct an original 
quantitative PCR system for CMV DNA, and to evaluate 
the analytical performance.
MATERIALS AND METHODS
Standard and clinical samples
Plasmid DNA, incorporating CMV glycoprotein B (gB) 
region (UL55), was made as a standard, the copy num-
ber of which was calculated based on mass and base 
length. The CMV DNA reference panels, which are 
derived from AD169 strain World Health Organization 
(WHO) International HCMV standard, were purchased 
from the National Institute for Biological Standards 
and Control (NIBSC, Ridge, Hertfordshire, UK). This 
material has been assigned a concentration of 5 × 106 
International Units (IU) when reconstituted in 1 mL of 
nuclease-free water.10 Archived 219 serum or plasma 
samples remaining after CMV antigenemia test were 
available at Tottori University Hospital, and stored at 
–20 ℃ until the study. Viral DNA was extracted from 
200 μL of serum or plasma using commercial DNA iso-
lation reagents (Qiagen, Tokyo, Japan). This study was 
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approved by the Ethics Committee at Tottori University 
Faculty of Medicine (approval number 2326).
Primer sets
Primers for the CMV gB region sequence were designed 
(Takara Bio, Kusatsu, Japan) as follows : forward primer 
5’-CCCTTGAGGTAGGGCGGTAG-3’, reverse primer 
5’-TGCGCGAATTCAACTCGTACA -3’, and TaqMan 
probe (FAM) 5’-ACCTTGTCCTCCACGTACTTTAC-
CCGCT-3’ (TAMRA).
Protocol
The RTD-PCR reaction was carried out in a 50 μL re-
action mixture containing 900 nM forward and reverse 
primer, 250 nM TaqMan Probe, 2 X TaqMan Universal 
PCR Master Mix (Applied Biosystems, Waltham, MA) 
and 5 μL template. The mixture was incubated at 50 ℃ 
for 2 minutes for initial activation of uracil-N-glycosy-
lase, followed by inactivation of uracil-N-glycosylase at 
95 ℃ for 5 minutes. Subsequent PCR amplifi cation con-
sisted of 60 cycles of denaturation at 95 ℃ at 15 seconds 
and annealing and extension at 60 ℃ for 1 minute in an 
ABI7300 Real-time PCR System (Applied Biosystems).
Evaluation of the RTD-PCR assay
Conversion of CMV DNA international units (IU) to 
copies/mL was evaluated by serial dilution of NIBSC 
standards from 106 to 102 IU/mL, with triplicates at ev-
ery dilution. Linearity of quantification by RTD-PCR 
system was evaluated as the log recovery for each mem-
ber of quality control panel. The lower detection limit 
was determined by 10-fold serial dilutions from 103 to 
101 IU/mL in 16 replicates. 
CMV antigenemia test
The CMV antigenemia test is used for detecting viral 
matrix phosphoprotein (pp65) in peripheral blood leu-
kocytes (PBLs) by indirect immunostain assay. Brieﬂ y, 
EDTA-treated whole blood samples were fractionated 
by dextran sedimentation and lysis of erythrocytes. The 
granulocytes were then centrifuged to prepare a cytospin 
slide (15,000 granulocytes per slide). The cells were then 
fixed with formaldehyde, sequentially immunostained 
by monoclonal antibodies C10/C11 (LSI CMV; LSI 
Medience, Tokyo, Japan), and reacted with goat alkaline 
phosphatase-labeled anti-mouse immunoglobulin as the 
second reaction. The examination was performed in du-
plicate. Measurement of the CMV antigenemia test was 
performed by LSI Medience.
Statistical analysis
For correlation analysis of obtained data, antigenemia 
results were reported as log10 pp65 positive cells/30,000 
examined and CMV DNA titers were also reported as 
log10 IU/mL. The differences between titers obtained by 
both quantitative tests were considered statistically sig-
nifi cant for P-value < 0.05, according to Mann-Whitney 
U test (SPSS statics 21; IBM, Armonk, NY).
RESULTS
Standards calibration and linearity
For the calibration of standards, two standard panels 
(pCMV gB, NIBSC) were cross-validated in the same 
reaction. Standard curves for CMV quantifi cation were 
established for each panel by serially diluting the stan-
dards from 106 to 102 copies/mL (IU/mL for NIBSC 
standard) and by amplifi cation in triplicates. We gener-
ated a log-linear regression plot by plotting the cycle of 
threshold (Ct) value. The correlation coeffi cients of the 
two different standards were 0.996 and 0.999, respec-
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Fig. 1. Standard curves generated by linear regression analysis of 
the Ct value measured for each amplifi cation versus the log10 virus 
copy number for each standard dilution. , WHO standard panel 
ranging from 106 IU/mL ; , plasmid pCMV_gB with original 106 
copies/mL. Ct, cycle of threshold; CMV, cytomegalovirus; gB, 
glycoprotein B; IU, international unit; WHO, World Health Orga-
nization; y, Ct value; R2, coeffi cient of determination. 
tively (Fig. 1). The two standards exactly corresponded 
to each other; the conversion factor was 1.02–1.07 cop-
ies/IU for each concentration (3–7 log copies or IU/mL). 
Low detection limit
Further validation of the lower limit of detection of 
RTD-PCR system was obtained by testing multiple rep-
licates of dilutions of the standard. Dilutions (equal to 
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1000, 500, 250, 125, 63, 31 IU/mL) were tested for 16 
replicates at each dilution. Using Probit analysis (IBM 
SPSS 21), the number of positive results at each dilution 
was used to calculate the CMV DNA concentration hav-
ing a 95% probability of detection (Table 1). The 95% 
detection limit was determined to be 556 IU/mL (95% 
CI, 440–797 IU/mL).
Table 1. RTD-PCR assay data used for probit analysis
CMV 
concentration 
(IU/mL)
Number 
positive/tested
Number 
expected 
positive
Probability
1000 16/16 15.999 1.000
500 14/16 14.583 0.911
250 9/16 8.248 0.516
125 5/16 4.301 0.269
62.5 4/16 2.761 0.173
31.3 2/16 2.143 0.134
0.0 0/16 1.628 0.102
CMV, cytomegalovirus; IU, international unit; RTD-PCR, re-
al-time detection polymerase chain reaction.
Specifi city
Twelve normal human sera were tested by both assays 
and all gave negative results. 
Reproducibility study
Inter-assay reproducibility was assessed by repeating 2 
samples of different concentrations, 1,000 IU/mL and 
10,000 IU/mL, in each of three different runs of RTD-
PCR. The coeffi cients of variations were 2.5% at 1,000 
IU/mL and 1.6% at 10,000 IU/mL. Intra-assay vari-
ability was evaluated by testing the same samples three 
times in a single run. The coeffi cients of variation were 
1.8–3.6% and 0.4–1.9% for the low and high concentra-
tions, respectively.
Comparison with CMV antigenemia test
All 219 clinical samples derived from 101 patients were 
analyzed both by the pp65 antigenemia test and the 
RTD-PCR system. Results of 90 were negative and 75 
were positive with both tests. On the contrary, 42 sam-
ples (19.1%) that tested negative by pp65 antigenemia 
were positive by PCR and showed moderate levels of 
CMV DNA (mean viral load 2.9 Log copies/mL) (Table 
2). Twelve samples were positive by the antigenemia test 
and negative by RTD-PCR. 
 In the case of PCR-positive samples more than or 
equal to 556 (2.7 log10) IU/mL, the CMV DNA levels 
of 62 pp65-positive samples and 32 pp65-negative sam-
ples were compared. The CMV DNA were signifi cantly 
higher in pp65 positive samples than in negative samples 
(Fig. 2A). In cases of samples with concordant positive 
results, the correlation between the number of CMV 
DNA log copies/mL of plasma or serum and the number 
of pp65 positive cells per 30,000 PBLs was statistically 
signifi cant (r = 0.695, P < 0.01) (Fig. 2B). None of the 
patients developed CMV-related symptoms. 
Table 2. Comparison between CMV DNA and pp65 
antigen results in the examined samples 
pp65 – pp65 + Total
CMV DNA – 90 12 102
CMV DNA + (< 2.7 Log10 IU/mL) 10 13 23
CMV DNA + (≥ 2.7 Log10 IU/mL) 32 62 94
CMV, cytomegalovirus; IU, international unit ; pp65 antigen, 
polypeptide 65 antigen ; RTD-PCR, real-time detection poly-
merase chain reaction.
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Fig. 2. Result of clinical samples. (A) CMV DNA loads of RTD-PCR in PCR-pos-
itive samples in relation to pp65 antigen results. (B) Correlation between CMV 
DNA load (log10 IU/mL) in serum or plasma samples and pp65 antigen values (log10 
positive cells/30,000 examined) among all samples testing positive by RTD-PCR 
assay. CMV, cytomegalovirus; IU, international; unit; pp65 antigen, polypeptide 65 
antigen; RTD-PCR, real-time detection polymerase chain reaction.
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Fig. 3
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Fig. 3. Patterns of pp65 antigen ( ) and CMV DNA ( ) in two patients. Patient A with diffuse large B-cell lymphoma 
developed bone marrow suppression. It became impossible to undergo the pp65 antigenemia test because of WBC ( ) 
decreased in number. Patient B underwent CBT. The period and dose of preemptive and steroid therapies are shown. CBT, 
cord blood transplantation; CMV, cytomegalovirus; GCV, ganciclovir; IU, international unit; pp65 antigen, polypeptide 65 
antigen; PSL, prednisolone; VGCV, valganciclovir; WBC, white blood cell.  
221
CMV DNA quantification system with RTD-PCR
Case study
We followed two immunosuppressed patients who had 
both tests (Fig. 3). Patient A with diffuse large B-cell 
lymphoma developed bone marrow suppression. By 
anti-viral therapy, pp65 antigen decreased immediately, 
while CMV DNA also decreased, however, remaining at 
high levels. After a while, it became impossible to per-
form the pp65 antigenemia test because of leukopenia. 
Patient B underwent cord blood transplantation (CBT). 
After CBT, both tests showed similar transient positive 
results. 
DISCUSSION
The amount of CMV DNA in blood is a result of the 
dynamic state between viral replication and clearance. 
Real-time PCR is a promising diagnostic approach for 
CMV infection after hematopoietic stem cell transplan-
tation or during chemotherapy since it is more suitable 
for standardization and easier to handle than the conven-
tional antigenemia assay. Furthermore, PCR system us-
ing plasma or serum can be used during leukocytopenia 
while the antigenemia assay does not produce reliable 
data without sufficient leukocytes.
 Currently, after the introduction of pre-emptive 
therapy with ganciclovir by monitoring with the CMV 
antigenemia test, CMV disease including CMV-related 
pneumonia is nearly preventable.11, 12 We developed a 
novel CMV DNA quantification system using an RTD-
PCR system targeting the gB gene. The coefficient of 
correlation between DNA quantity and Ct value was r > 
0.99, indicating good linearity. And good reproducibility 
and a wide dynamic range (102–106 IU/mL) were shown. 
The lower limit of quantification (556 IU/mL) is inferi-
or to that of the commercial PCR kit (150 copies/mL, 
Roche Diagnostics, Basel, Switzerland). There are two 
methods of RTD-PCR that amplify CMV US17 region 
(US17-PCR) and immediate early (IE) gene (IE-PCR). 
Different sensitivity and threshold to start ganciclovir 
were reported for each method.13 And the thresholds of 
the viral load to initiate preemptive therapy were also 
different according to clinical situations. For example, in 
the study of solid organ transplant recipients evaluating 
RTD-PCR of plasma and pp65 antigenemia, an antigen-
emia threshold value of 20 positive cells/20,000, was 
equivalent to 2500 copies/mL (2275 IU/mL) for antiviral 
treatment.14 In case of hematopoietic stem cell transplant 
recipients from unrelated donors, a much lower threshold 
of CMV DNA titer was used for preemptive therapy.15 
 The present study shows a good correlation between 
antigenemia and plasma or serum CMV DNA levels (r 
= 0.695). The novel assay also showed more usefulness 
in monitoring the CMV reactivation of patients with 
leukopenia or myelosuppression than antigenemia test 
(patient A in Fig. 3). Both antigenemia and CMV DNA 
load deceased after the initiation of therapy. In addition, 
antigenemia assay and RTD-PCR system showed a 
similar trend (patient B in Fig. 3). These results indicate 
that using the RTD-PCR system to monitor quantities of 
CMV DNA could be useful in ganciclovir treatment. 
 Twelve samples were pp65 positive and CMV DNA 
negative while 42 samples were reverse. The targets of 
the two methods are different; RTD-PCR amplifies free 
CMV DNA in plasma and the CMV antigenemia test 
detects pp65 antigens in peripheral blood leukocytes. 
Which target is appropriate for monitoring CMV in-
fection for clinical use remains to be determined. Their 
combination may explain virus status more accurately.
 In conclusion, we constructed a RTD-PCR system 
which has sufficient sensitivity, specificity, accuracy, 
and reproducibility. Quantification can be performed 
within three hours without false-positive results. Based 
on our results, the RTD-PCR system appears to be as 
useful as any commercial CMV quantification system. 
Furthermore, it may be useful for patients to consider 
comprehensively the results of RTD-PCR and CMV an-
tigenemia test.
The authors declare no conflict of interest.
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